KPTI Karyopharm Therapeutics Inc.

8.95
-0.14  -2%
Previous Close 9.09
Open 9.09
Price To book 2.75
Market Cap 421.71M
Shares 47,118,000
Volume 91,491
Short Ratio 5.85
Av. Daily Volume 357,367

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 updated data presented at ASH 2016.
Selinexor - SAIL
Acute myeloid leukemia (AML)
Phase 2 initiated April 2014. Interim data at ASCO 2015
Selinexor - (KING study)
Cancer - glioblastoma
Phase 2/3 trial initiated January 2016. Top-line data for the Phase 2 portion due mid-2017.
Selinexor - SEAL
Dedifferentiated liposarcoma
Phase 2 positive top-line data released September 6, 2016. Updated data at ASH 2016. Top-line data from expansion cohort due early 2018.
Selinexor - STORM
Quadruple Refractory Multiple Myeloma
Phase 3 trial to be initiated May 2017.
Selinexor - BOSTON
Multiple myeloma
Phase 2b additional interim data released April 4, 2017 at AACR. Final top-line data due mid-2018.
Selinexor - SADAL
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Data Safety Monitoring Board (DSMB) noted March 2, 2017 that trial will not meet primary endpoint.
Selinexor SOPRA
Cancer - Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 2 data presented at ASCO 2015. Phase 3 trial to be initiated late 2017.
Selinexor (SIGN Study)
Cancer - Advanced Gynecologic Malignancies (SIGN Study)
Phase 2 trial terminated.
Selinexor - SIRRT
Richter's transformation
Phase 2 trial terminated.
Selinexor - SHIP
Cancer - hormone-refractory prostate cancer (HRPC)

Latest News

  1. Karyopharm’s Phase 2b SADAL Data Evaluating Selinexor in Diffuse Large B-Cell Lymphoma Selected for Oral Presentation at the 2017 European Hematology Association Annual Meeting
  2. Edited Transcript of KPTI earnings conference call or presentation 4-May-17 12:30pm GMT
  3. Karyopharm Therapeutics posts 1Q loss
  4. Investor Network: Karyopharm Therapeutics, Inc. to Host Earnings Call
  5. Karyopharm Reports First Quarter 2017 Financial Results and Highlights Recent Progress
  6. Karyopharm and Anivive Lifesciences Sign Exclusive Global License Agreement for Verdinexor for Animal Health Applications
  7. Karyopharm Therapeutics, Inc. – Value Analysis (NASDAQ:KPTI) : April 27, 2017
  8. Karyopharm to Report First Quarter 2017 Financial Results on May 4, 2017
  9. Karyopharm Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : KPTI-US : April 26, 2017
  10. Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
  11. Newton cancer biotech Karyopharm plans to raise $40M in stock sale
  12. Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock
  13. Six Stocks Spiking Up With Huge Volume
  14. Why Karyopharm Therapeutics Inc Stock Gained 16.4% in March
  15. Karyopharm Reports Interim Phase 2b SADAL Data at the 2017 American Association for Cancer Research Annual Meeting
  16. Karyopharm and Medidata Expand Clinical Trial Partnership
  17. Karyopharm Announces Management Change
  18. Karyopharm to Present Selinexor Phase 2b SADAL Data at the American Association for Cancer Research Annual Meeting 2017
  19. U.S. FDA Division of Hematology Products Lifts Partial Clinical Hold on Karyopharm’s Selinexor Clinical Trials

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17813959
  2. 8-K - Current report 17811780
  3. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17795501
  4. DEF 14A - Other definitive proxy statements 17795433
  5. 8-K - Current report 17784371
  6. 424B5 - Prospectus [Rule 424(b)(5)] 17784313
  7. 424B5 - Prospectus [Rule 424(b)(5)] 17778407
  8. 8-K - Current report 17742676
  9. 8-K - Current report 17741023
  10. 8-K - Current report 17738242